SureTrader Nadex Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski
Search This Board: 
Last Post: 2/23/2017 1:44:15 PM - Followers: 136 - Board type: Free - Posts Today: 0


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS
Current Price
Volume:
Bid Ask Day's Range
SureTrader
OXIS News: Current Report Filing (8-k) 02/17/2017 05:17:13 PM
OXIS News: Amended Statement of Ownership (sc 13g/a) 02/13/2017 01:42:09 PM
OXIS News: Securities Registration Statement (s-1/a) 02/10/2017 05:22:26 PM
OXIS News: Amended Statement of Ownership (sc 13g/a) 02/10/2017 04:50:19 PM
OXIS News: Current Report Filing (8-k) 02/09/2017 05:14:05 PM
PostSubject
#8506   it hasnt yet......man you guys are too much tommer 02/23/17 01:44:15 PM
#8505   wow, never thought that would happen Fibanotch 02/23/17 01:23:34 PM
#8504   .01-.02 cents by close or tomorrow HorseShoe Man 02/23/17 12:14:25 PM
#8503   This issued shares will only cause this to HorseShoe Man 02/23/17 09:52:03 AM
#8502   Looks like MM's banked today. Gibba 02/21/17 04:45:41 PM
#8501   Again, why file and put damaging (potentially) information Gibba 02/21/17 03:50:34 PM
#8500   actually you posted that it was already authorized.... tommer 02/21/17 01:08:09 PM
#8499   I just copied the PR word for word Gibba 02/21/17 12:57:17 PM
#8498   59 million is the correct share count... tommer 02/21/17 12:37:57 PM
#8497   The reason u r seeing 8 KS is tommer 02/21/17 12:11:07 PM
#8496   You have been set straight on this already And tommer 02/21/17 12:07:39 PM
#8495   If you look at the 8-k just filed scoot27 02/21/17 11:45:48 AM
#8494   I did notice a lot of T trades daily glens0 02/21/17 11:00:31 AM
#8493   Isn't over 500 million to be Authorized? Gibba 02/21/17 10:54:04 AM
#8492   I meant what is the market size for BondAssets 02/21/17 10:37:10 AM
#8491   OXIS Security Details glens0 02/21/17 10:16:45 AM
#8490   Just like I said last night! Great Patents BondAssets 02/21/17 10:15:23 AM
#8489   http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128859929 glens0 02/21/17 10:10:17 AM
#8488   RIGATONI   glens0 02/21/17 10:03:55 AM
#8487   My average is now 0.0918478239 BondAssets 02/20/17 10:16:54 PM
#8486   Hello BondAssets. If I may ask what is jimbosskow 02/20/17 08:14:46 PM
#8485   This stock has huge potential, valuable patents filled... BondAssets 02/20/17 07:32:38 PM
#8483   Simon - true on all points. Gibba 02/15/17 02:40:40 PM
#8482   Don't have to be a "big boy" to simon wagstaff 02/15/17 11:17:42 AM
#8481   Day trade, different from investing. That is what Gibba 02/15/17 10:32:57 AM
#8480   Buy fear sell happiness. jimbosskow 02/14/17 08:05:29 PM
#8479   You never told me anything. Big boys? Meaning what? simon wagstaff 02/14/17 07:31:02 PM
#8478   Told you OXIS is for the big boys... jimbosskow 02/14/17 05:58:57 PM
#8477   Good luck with that simon wagstaff 02/14/17 05:30:41 PM
#8476   Me. :) jimbosskow 02/14/17 05:15:47 PM
#8475   Seems like the debt paid with the stock Gibba 02/14/17 02:33:48 PM
#8474   I would also like to hear from anyone Rando3 02/14/17 02:19:04 PM
#8473   To me, that's the piece I'm missing. If Rando3 02/14/17 02:13:11 PM
#8472   I used to like this "company"....man I took djmurdock 02/14/17 01:56:53 PM
#8471   Based on a number of outstanding equal to tommer 02/14/17 01:04:04 PM
#8470   Depends on where I got in but Hey That is tommer 02/14/17 12:32:58 PM
#8469   Me too. Fortunately my son (and I) wanted Gibba 02/14/17 09:58:47 AM
#8468   Right, I would like to average down. It heaviestD 02/14/17 12:14:12 AM
#8467   Where is the line? That way I know Gibba 02/13/17 10:44:30 PM
#8466   Ok, the first step. You know what comes Gibba 02/13/17 10:43:07 PM
#8465   Relax, just hold the line and you will jimbosskow 02/13/17 07:01:42 PM
#8464   that is the facts....some here like to predict tommer 02/13/17 06:48:48 PM
#8463   If you are talking about the Information in scoot27 02/13/17 05:29:46 PM
#8462   I think it is 300 million authorized to Gibba 02/13/17 02:43:29 PM
#8461   All of the stock issued to pay off scoot27 02/13/17 01:41:28 PM
#8460   Seems a bit weird to me that they simon wagstaff 02/13/17 10:40:13 AM
#8458   tommer, you must still be holding. Gibba 02/13/17 09:56:02 AM
#8454   Fear Mongering? No, Facts. Gibba 02/12/17 09:43:22 PM
#8451   Bounce from 300 Million Additional shares being authorized Gibba 02/12/17 05:04:27 PM
#8450   This will bounce soon, watching Chunky Salsa 02/11/17 10:03:04 PM
PostSubject